Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1996 Mar;51(3):323–324. doi: 10.1136/thx.51.3.323

Compliance with oral corticosteroids during steroid trials in chronic airways obstruction.

M Q Hatton 1, M B Allen 1, S V Vathenen 1, M P Feely 1, N J Cooke 1
PMCID: PMC1090650  PMID: 8779142

Abstract

BACKGROUND: Corticosteroid trials are an important part of the assessment of patients with chronic airways obstruction, but false negative results will occur if the treatment is not taken. To determine compliance low dose phenobarbitone has been used as a marker. METHODS: Thirty six patients referred to a chest clinic for assessment of their airways obstruction were studied. They were instructed to take eight capsules (each containing 5 mg prednisolone and 0.5 mg phenobarbitone) per day for two weeks. The response was assessed by home peak flow monitoring and clinic spirometric tests. Plasma phenobarbitone levels were measured after the trial to enable calculation of the dose to plasma concentration ratio (level to dose ratio, LDR) and the result was compared with the reference range for fully compliant individuals. RESULTS: Five patients defaulted from follow up, 23 had LDR values within the expected range, and eight had low LDR values consistent with poor compliance. The nine patients with steroid responsive disease (> 20% improvement in peak flow or spirometric parameters) all had LDR values in the expected range. CONCLUSION: Excluding those who defaulted whose compliance must be questionable, eight (26%) patients did not fully comply with the steroid trial. Not all patients who fail to respond to a two week home steroid trial have a steroid "unresponsive" disease.

Full text

PDF
323

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bignell C. J., Mulcahy F. M., Peaker S., Pullar T., Feely M. P. Measuring treatment compliance of men with non-gonococcal urethritis receiving oxytetracycline combined with low dose phenobarbitone. Genitourin Med. 1988 Oct;64(5):312–315. doi: 10.1136/sti.64.5.312. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Feely M., Cooke J., Price D., Singleton S., Mehta A., Bradford L., Calvert R. Low-dose phenobarbitone as an indicator of compliance with drug therapy. Br J Clin Pharmacol. 1987 Jul;24(1):77–83. doi: 10.1111/j.1365-2125.1987.tb03139.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Levine R. J. Monitoring for adherence: ethical considerations. Am J Respir Crit Care Med. 1994 Feb;149(2 Pt 1):287–288. doi: 10.1164/ajrccm.149.2.8306018. [DOI] [PubMed] [Google Scholar]
  4. Price D. E., Mehta A., Park B. K., Hay A., Feely M. P. The effect of low-dose phenobarbitone on three indices of hepatic microsomal enzyme induction. Br J Clin Pharmacol. 1986 Dec;22(6):744–747. doi: 10.1111/j.1365-2125.1986.tb02970.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Thornton H. Understanding "informed consent". Lancet. 1995 Oct 21;346(8982):1047–1048. doi: 10.1016/s0140-6736(95)91735-7. [DOI] [PubMed] [Google Scholar]
  6. Weir D. C., Gove R. I., Robertson A. S., Burge P. S. Corticosteroid trials in non-asthmatic chronic airflow obstruction: a comparison of oral prednisolone and inhaled beclomethasone dipropionate. Thorax. 1990 Feb;45(2):112–117. doi: 10.1136/thx.45.2.112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Wright E. C. Non-compliance--or how many aunts has Matilda? Lancet. 1993 Oct 9;342(8876):909–913. doi: 10.1016/0140-6736(93)91951-h. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES